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expression for 96% (BT-474) and 93% (MCF7) of the cell line
population with MFI ratios of 46 and 26, respectively. Only
BT-474 showed an amplification of the Her/neu oncogene  by
FISH. Comparisons of frequencies were performed using Pear-
son’s χ2 test. Overall (OS) and disease-free (DFS) survivals
were estimated by the Kaplan-Meier product limit method.
Curves were compared by the stratified log-rank test. 
Fifteen B-ALL patients were found to be positive for sur-
face Her2/neu expression, including 2 children and 13
adults, 11 male and 4 females. The median percentage of
Her2/neu positive blasts was 94% (range: 11-99%). The
median MFI was 7.7 (range: 3.5-54.5). The incidence of
positivity in children was only 3.4% (2/59) compared to
31% in adults (13/41) (p=0.001). None of the positive B-
ALL patients showed gene amplification, as detected by
FISH analysis, suggesting that another mechanism is
involved, such as transcriptional activation or post-trans-
lational modifications. Considering only adult B-ALL
patients (n=38, median follow-up: 11 months, range (1-
113)), in whom the main prognostic parameters and treat-
ment (70% of patients were treated according to or in the
GOELAL2 trial) did not differ significantly between
Her2/neu positive and negative patients (Table 1), we
observed that surface Her2/neu expression was associat-
ed with chemoresistance (50% versus 11%, p=0.03). Fur-
thermore, trends for correlation with refractory disease
(41% versus 11%, p=0.08) and disease relapse (55% ver-
sus 36%, p=0.08) were observed, suggesting that surface
Her-2/neu expression could be a prognostic marker of poor
clinical outcome in ALL. However, overall survival (medi-
an 9 months versus 18 months, p=0.17) and disease-free
survival in patients with complete remission (median 11
months versus 39 months, p=0.27) were similar between
the two groups. This may be due to the small number of
patients in the series, but also because, in the same pro-
portion of Her2/neu negative patients, some patients
received autologous or allogeneic stem cell transplants
because of the poor results of the first chemotherapy.
Target-directed signal transduction inhibition therapy
using anti Her2/neu monoclonal antibody might be a ther-
apeutic possibility in this selected group of poor-risk adult
B-ALL patients. We are currently conducting a phase II tri-
al of efficacy and tolerance of trastuzumab in adult
Her2/neu positive relapsed/refractory B-ALL patients.
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Malignant Lymphomas
Methylation status of the p15, p16 and MGMT promoter
genes in primary cutaneous T-cell lymphomas
p15INK4b, p16INK4a and O6-methylguanine DNA methyl-
transferase (MGMT) gene hypermethylation was studied
in 22 patients with primary cutaneous T-cell lymphomas
(CTCL). p15INK4b and p16INK4a inactivation is present in ear-
ly and advanced disease and seems to be independent of
disease stage. MGMT inactivation may play a patho-
genetic role in a subset of CTCL.
haematologica 2004; 89:1401-1403
(http://www.haematologica.org/2004/11/1401)
Transcriptional repression by hypermethylation of pro-
moter sequences has been postulated as a possible way in
which tumor suppressor genes are inactivated in cancer.
Inactivation of the INK4 family (composed of p15INK4b,
p16INK4a, p18INK4c, and p19INK4d) may lead this mechanism in
several malignant neoplasms.1 Promoter hypermethylation
in p15INK4b and p16INK4a seems to be major mechanism of inac-
tivation in both B- and T-cell hematologic malignancies.
These phenomena occur as independent events and seem to
occur with a tumor-specific pattern. Homozygous deletions
also play a role in 10-40% of the cases depending on the
subtype, however, mutations in these genes are rarely
detected in leukemias and lymphomas.2-4
MGMT is a DNA repair enzyme that protects cells from
alkylating agents that frequently target the O6-position of
guanine. Methylation-associated silencing of MGMT has
been described in many human neoplasms, and may predict
good response to alkylating agents. However, MGMT could
also play a role in the protection against carcinogenesis
and its inactivation has also been implicated in the gener-
ation of transition mutations in K-ras and p53 genes.5,6
Twenty-two patients with CTCL were included in the
study (9 with patch/plaque mycosis fungoides (MF); 6 with
tumoral MF; 1 with Sézary’s syndrome, and 6 with periph-
eral T-cell lymphoma primarily arising in the skin).
CpG island methylation status was analyzed as previ-
ously described. In brief, DNA was modified by sodium bisul-
fite and a subsequent methylation-specific polymerase
chain reaction (PCR) was carried out using primers designed
for methylated and unmethylated p15INK4b, p16INK4a and
MGMT promoter genes. DNA from normal lymphocytes was
used as the negative control for unmethylated alleles and
DNA methylated in vitro with the bacterial methyltrans-
ferase Sss I was used as the positive control (Figure 1).
Selective hypermethylation of either the p15INK4b or p16INK4a
gene occurred in 13 out of 22 cases (59%). Hypermethyla-
tion of the p15INK4b gene was detected in 4/6 patients (66%)
with tumor-stage MF, and in one patient with plaque stage
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MF. This last patient presented MF associated with lym-
phomatoid papulosis, and both lesions showed hyperme-
thylation in the p16INK4a gene. p15INK4b was the only gene
hypermethylated in the patient with Sézary’s syndrome. Two
out of 6 (33%) of the patients with peripheral T-cell lym-
phoma had p15INK4b gene inactivation. Conversely, hyperme-
thylation of the p16INK4a gene was found in 4/9 (44%)
patients with plaque stage MF, but in only one case of 6
(16%) with  tumor-stage MF. Of the 6 patients  with periph-
eral lymphoma, 3 (50%) showed hypermethylation of the
p16INK4a gene. MGMT methylation was demonstrated in 8
out 22 skin biopsies (36%). One patient with plaque stage
MF, 2/6 with tumor-stage MF and 5/6 biopsy specimens
(84%) from peripheral T-cell lymphomas showed this alter-
ation (Table 1). Navas et al. detected p16INKa alterations
(hypermethylation and/or allelic loss) in 7 out of 9 MF
tumor-stage lesions. Alterations in p16INKa and p15INKb were
detected in 18% and 5%, respectively, of patients with ear-
ly MF but in 73% and 27%, respectively, of those with
aggressive MF. The authors postulated that p16INKa inacti-
vation could be a necessary step for tumor progression in
MF, but that additional changes are required to allow or
accelerate it.7,8
In contrast, Scarisbrick et al. detected allelic loss on 9p21
in 25% of a large series of CTCL cases. Hypermethylation of
p16INKa and p15INK4b genes was demonstrated in 29% and
45%. These abnormalities seemed not to be dependent on
the stage of the disease. Hypermethylation of the p16INK4a
gene was not identified in any of the cases of Sézary’s syn-
drome, although 5/12 (42%) patients had hypermethylation
of the p15INK4b gene. Our results regarding p15INK4b and p16INK4a
gene methylation seem to support these latter results.9
We have demonstrated a high frequency of MGMT hyper-
methylation (84%) in primary cutaneous peripheral T-cell
Table 1. Clinical data and methylation status in MGMT and p15/p16 promoter genes.
Subtype Cases Sex Age range Staging GSA Response to AA* Clinical status Methylation status
M:F [mean] treatments & follow-up MGMT p16 p15
CD30-CTCL 6 2:4 40-60 [54] IIB (n=3) C (4/6) CR (n=1) D (n=6) M (n=5) M (n=3) M (n=2)
IVB (n=3) PR (n=2), 1-4 y  [2.3] U  (n=1) U (n=3) U (n=4)
PD (n=3)
MFt 6 1:5 52-68 [45.5] IIB (n=5) C (2/4) CR (n=1) CR (n=1) M (n=2) M (n=1) M (n=4)
IVB (n=1) PR (n=2), AD (n=2) U (n=4) U (n=5) U (n=2)
PD (n=1) D (n=1)
6-14 y [12] 
MFp 9 6:3 48-66 [58.5] IA (n=3) C (6/9) PR (n= 1) AD (n=1) M (n=1) M (n=4) M (n=1)
IB (n=5) 3-12 y [6.4] U (n=8) U (n=5) U (n=8)
IVA (n=1)
SS 1 M 31 IVA C PR D 2y U U M
CD30-CTCL: cutaneous CD30 negative large T-cell lymphoma; MFt: mycosis fungoides tumor stage; MFp: patch/plaque stage; SS: Sézary’s syndrome; M: male; F: female;
GSA: GeneScan Analysis; C: clonal (monoclonal cases/analyzed cases); *AA: patients treated with alkylating agents (CHOP: cyclophosphamide, adryamycin, oncovin, pred-
nisone); CR: complete response; PR: partial response; PD: progressive disease; D: death (died of lymphoma); y: years; AD: alive with active disease; M: hypermethylated
(inactive); U: unmethylated (active).
Figure 1. Analysis by methylation specific-PCR polymerase chain reaction of the CpG island  methylation status of
the MGMT, p15INK4b and p16INK4a gene promoters. The presence of a visible PCR product in those lanes marked U indi-
cates the presence of unmethylated genes; the presence of a visible PCR product in those lanes marked M indicates
the presence of methylated genes. In vitro methylated DNA (IVD) was used as a positive control and water (H2O) as
a negative PCR control. MGMT is methylated in the sample from patient #2, p15INK4b is methylated in the sample from





M M U M U M
1 2 H2O 3 4 5 6 IVD
U M U M U M U M M U M U M U M
7 8 9
haematologica 2004; 89(11):November 2004
Letters to the Editor
1403
lymphoma. As far as we know, this phenomenon has not
been previously reported, and the significance of this obser-
vation remains elusive. In addition, in our series MGMT
hypermethylation does not seem to play a significant role
in the response to chemotherapy in CTCL patients. The pos-
sibility that MGMT hypermethylation may  be a negative
prognostic factor identifying a specific subset of lymphomas
cannot be completely ruled out.
In conclusion, our results demonstrate that hypermethy-
lation in p15INK4b and p16INK4a promoter genes seems to play
a role in the pathogenesis of cutaneous T-cell lymphoma.
These phenomena occur independently as tumor-specific
events and probably are not-dependent on the stage of the
disease. MGMT promoter hypermethylation occurs in a sig-
nificant percentage of T-cell cutaneous lymphomas. 
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Blood Doping
Longitudinal variation of hemoglobin and reticulocytes in
elite rowers
Longitudinal monitoring of athlete’s hematologic
parameters holds considerable promise as a strategy to
detect and thereby deter illicit blood doping. This study
documents temporal changes of hemoglobin concentra-
tion (Hb) and reticulocyte counts in elite rowers. The
‘within subject’ variation in rowers was comparable to
that of athletes from other sports. Reticulocyte results
were dependent on the type of instrument used.
haematologica 2003; 89:1403-1404
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The concept of utilizing a Hematologic passport as a tool
to highlight athletes who have used illegal blood doping to
enhance performance is gaining credibility. Faced with a
limited budget, anti-doping authorities must balance the
frequency of testing with the scope of hematologic evalu-
ation. Two cornerstones of this approach will be Hb con-
centration and reticulocyte counts, which can both be
measured on portable analyzers relocated to the event ven-
ue. Thus samples collected at the time of competition for
routine blood screens could also provide a cost-effective
and convenient source of Passport data.
A crucial element of the Passport approach is to define in
advance normal fluctuations in blood parameters, to enable
authorities to discriminate between expected and suspect
changes. It is also necessary to recognize whether biologi-
cal variability is sport-specific or whether such changes are
universal across different sports. The first aim of this
research was to report the variation of Hb and reticulocytes
in rowers, and then to contrast these with data reported
previously for athletes from another discipline. A second
aim was to verify whether it was tenable to compare hema-
tologic results obtained on different instruments. 
Blood samples were obtained from members of the French
National Rowing squad (n=83 males, n=31 females).
Between two and eight (average  4.8 males and 3.7 females)
EDTA blood samples were collected from each rower
between July 2001 and March 2004, and were measured on
either an ADVIA 120 Hematology Analyzer or a Sysmex
Roche XE2100 (instruments were calibrated according to
manufacturers’ specifications). To provide heightened res-
olution reticulocytes are reported on a square root scale.1
These results were contrasted with previously reported data
comprising longitudinal evaluations from a subset of n=288
male professional football players measured on average 2.9
times between May 1999 and July 2002.2 Analysis of vari-
ance was used to partition the total variation present in
each data set into three components: the variation within
subjects, the variation between days (within instruments)
and the variation between subjects.
Table 1 gives estimates of the variances. In each case the
estimate allows for the other two components of variation.
All of the between subject and between days variances are
significantly greater than zero (F-test, p ≤ 0.001). The esti-
mates show that the within subject variance for both Hb and
reticulocytes is comparable among (male) football players
and rowers. For Hb the between subject variances for males
are comparable (estimates are at least double those of the
within subject estimates, although lower for females). In
